Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of elacycline-based combination therapy for carbapenem-resistant gram-negative infections
ChiCTR2400081191Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital of Traditional Chinese Medicine
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elacycline in Carbapenem-resistant Acinetobacter baumannii infection (CRAB), Carbapenem-resistant Klebsiella pneumoniae infection (CRKP) and Stenotrophomonas infection, sponsored by Zhejiang Hospital of Traditional Chinese Medicine. Primary endpoint: Clinical effective rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
elacycline
03
Conditions
Carbapenem-resistant Acinetobacter baumannii infection (CRAB)Carbapenem-resistant Klebsiella pneumoniae infection (CRKP)Stenotrophomonas infection
Beyond the preview
Go deeper on ChiCTR2400081191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081191.